NCT04657068
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ATM
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Chemotherapy, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have at least 1 radiologically evaluable lesion; Patients with a BRCA mutation (germline or somatic) for which there is an approved PARP inhibitor should have received such treatment before participating in the study unless contra-indicated; Only breast cancer patients with tumors that express a loss of ATM protein by IHC are eligible for the dose expansion (Part B1)
Exclusions: Patients that have received previous treatment targeting the ATR/CHK1 pathway; Patients with symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment
https://ClinicalTrials.gov/show/NCT04657068